Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: A real-life data of the Turkish Oncology Group

Basit Öğe Kaydı
dc.authorid0000-0003-2184-634X
dc.authorid0000-0002-0443-6966
dc.authorid0000-0001-7934-7039
dc.contributor.authorGürbüz, Mustafa
dc.contributor.authorKutlu, Yasin
dc.contributor.authorAkkuş, Erman
dc.contributor.authorKöksoy, Elif Berna
dc.contributor.authorKöse, Naziyet
dc.contributor.authorÖven, Bala Başak
dc.contributor.authorOyan Uluç, Başak
dc.contributor.authorDemiray, Atike Gökçen
dc.contributor.authorErdem, Dilek
dc.contributor.authorDemir, Bilgin
dc.contributor.authorTurhal, Nazım Serdar
dc.contributor.authorÜskent, Necdet
dc.contributor.authorAkbaş, Sinem
dc.contributor.authorSelçukbiricik, Fatih
dc.contributor.authorİnal, Ali
dc.contributor.authorBilici, Ahmet
dc.contributor.authorÖlmez, Ömer Fatih
dc.contributor.authorÇabuk, Devrim
dc.contributor.authorÜnal, Çağlar
dc.contributor.authorHizal, Mutlu
dc.contributor.authorŞendur, Mehmet Ali Nahit
dc.contributor.authorKorkmaz, Mustafa
dc.contributor.authorKaradurmuş, Nuri
dc.contributor.authorErtürk, İsmail
dc.contributor.authorGöksu, Sema Sezgin
dc.contributor.authorTatlı, Ali Murat
dc.contributor.authorGüven, Deniz Can
dc.contributor.authorKılıçkap, Saadettin
dc.contributor.authorPaksoy, Nail
dc.contributor.authorAydıner, Adnan
dc.contributor.authorYeşil Çınkır, Havva
dc.contributor.authorÖzkul, Özlem
dc.contributor.authorÖztürk, Akın
dc.contributor.authorBallı, Sevinç
dc.contributor.authorKemal, Yasemin
dc.contributor.authorErdoğan, Atike Pınar
dc.contributor.authorEr, Özlem
dc.contributor.authorYumuk, Perran Fulden
dc.contributor.authorDemirkazık, Ahmet
dc.date.accessioned2022-11-15T11:32:10Z
dc.date.available2022-11-15T11:32:10Z
dc.date.issued2022
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractPurpose Atezolizumab has been shown to be effective and safe in randomized trial in the first-line treatment of extensive-stage small cell lung cancer (SCLC). However, there are limited real-life data on atezolizumab. In this study, we aimed to determine the real-life efficacy and safety of atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage SCLC. Methods This trial is a retrospective multicenter study of the Turkish Oncology Group, which included extensive-stage SCLC patients who received atezolizumab combined with chemotherapy in a first-line treatment. The characteristics of the patients, treatment and response rates, and PFS and OS are presented. Factors associated with PFS and OS were analyzed by univariate and multivariate analysis. Results A total of 213 patients at the 30 oncology centers were included. The median number of chemotherapy cycle was 5 (1-8) and atezolizumab cycle was 7 (1-32). After median 11.9 months of follow-up, median PFS and OS was 6.8 months (95%CI 5.7-7.8), and 11.9 months (95%CI 11-12.7), respectively. The ORR was 61.9%. ECOG-PS (p = 0.002) and number of metastatic sites (p = 0.001) were associated with PFS and pack-year of smoking (p = 0.05), while ECOG-PS (p = 0.03) and number of metastatic sites (p = 0.001) were associated with OS. Hematological side effects were common and toxicities were manageable. Conclusion This real-life data confirm the efficacy and safety of atezolizumab in combination with chemotherapy in first-line treatment of extensive-stage SCLC.
dc.identifier.citationGürbüz, M., Kutlu, Y., Akkuş, E., Köksoy, E. B., Köse, N., Öven, B. B. ... Demirkazık, A. (2022). Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: A real-life data of the Turkish Oncology Group. Journal of Cancer Research and Clinical Oncology, 148(12), 3547-3555. https://doi.org/10.1007/s00432-022-04087-x
dc.identifier.doi10.1007/s00432-022-04087-x
dc.identifier.endpage3555
dc.identifier.issn0171-5216
dc.identifier.issn1432-1335
dc.identifier.issue12
dc.identifier.pmid35689097
dc.identifier.scopus2-s2.0-85131510571
dc.identifier.scopusqualityQ1
dc.identifier.startpage3547
dc.identifier.urihttps://doi.org/10.1007/s00432-022-04087-x
dc.identifier.urihttps://hdl.handle.net/20.500.12511/9964
dc.identifier.volume148
dc.identifier.wos000809330900001en_US
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorKutlu, Yasin
dc.institutionauthorBilici, Ahmet
dc.institutionauthorÖlmez, Ömer Fatih
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofJournal of Cancer Research and Clinical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAtezolizumab
dc.subjectPD-L1
dc.subjectSmall Cell Lung Cancer
dc.subjectImmunotherapy
dc.titleAtezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: A real-life data of the Turkish Oncology Group
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu